157 related articles for article (PubMed ID: 28349292)
1. In Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2'-deoxy-2'-fluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetically Modified Mouse Pancreatic Cancer Models.
Russell J; Pillarsetty N; Kramer RM; Romesser PB; Desai P; Haimovitz-Friedman A; Lowery MA; Humm JL
Mol Imaging Biol; 2017 Dec; 19(6):885-892. PubMed ID: 28349292
[TBL] [Abstract][Full Text] [Related]
2. Predicting Gemcitabine Delivery by
Russell J; Grkovski M; O'Donoghue IJ; Kalidindi TM; Pillarsetty N; Burnazi EM; Kulick A; Bahr A; Chang Q; LeKaye HC; de Stanchina E; Yu KH; Humm JL
J Nucl Med; 2021 Feb; 62(2):195-200. PubMed ID: 32646874
[No Abstract] [Full Text] [Related]
3. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
Lee JT; Campbell DO; Satyamurthy N; Czernin J; Radu CG
J Nucl Med; 2012 Feb; 53(2):275-80. PubMed ID: 22302964
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor efficacy of the nucleoside analog 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl) cytosine (4'-thio-FAC) in human pancreatic and ovarian tumor xenograft models.
Zajchowski DA; Biroc SL; Liu HL; Chesney SK; Hoffmann J; Bauman J; Kirkland T; Subramanyam B; Shen J; Ho E; Tseng JL; Dinter H
Int J Cancer; 2005 May; 114(6):1002-9. PubMed ID: 15645422
[TBL] [Abstract][Full Text] [Related]
5. Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment.
Braas D; Ahler E; Tam B; Nathanson D; Riedinger M; Benz MR; Smith KB; Eilber FC; Witte ON; Tap WD; Wu H; Christofk HR
Cancer Discov; 2012 Dec; 2(12):1109-17. PubMed ID: 23230188
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography.
Laing RE; Walter MA; Campbell DO; Herschman HR; Satyamurthy N; Phelps ME; Czernin J; Witte ON; Radu CG
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2847-52. PubMed ID: 19196993
[TBL] [Abstract][Full Text] [Related]
7. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
8. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine with gemcitabine in its antitumor activity.
Miura S; Yoshimura Y; Endo M; Satoh H; Machida H; Sasaki T
Cancer Lett; 1999 Oct; 144(2):177-82. PubMed ID: 10529018
[TBL] [Abstract][Full Text] [Related]
10. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
Damaraju VL; Bouffard DY; Wong CK; Clarke ML; Mackey JR; Leblond L; Cass CE; Grey M; Gourdeau H
BMC Cancer; 2007 Jul; 7():121. PubMed ID: 17608948
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine.
Kimura K; Sawada T; Komatsu M; Inoue M; Muguruma K; Nishihara T; Yamashita Y; Yamada N; Ohira M; Hirakawa K
Clin Cancer Res; 2006 Aug; 12(16):4925-32. PubMed ID: 16914581
[TBL] [Abstract][Full Text] [Related]
12. Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line.
Kazuno H; Sakamoto K; Fujioka A; Fukushima M; Matsuda A; Sasaki T
Cancer Sci; 2005 May; 96(5):295-302. PubMed ID: 15904471
[TBL] [Abstract][Full Text] [Related]
13. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
[TBL] [Abstract][Full Text] [Related]
14. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets.
Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
Int J Cancer; 2012 Aug; 131(3):E292-303. PubMed ID: 21935918
[TBL] [Abstract][Full Text] [Related]
15. (18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts.
Shah N; Zhai G; Knowles JA; Stockard CR; Grizzle WE; Fineberg N; Zhou T; Zinn KR; Rosenthal EL; Kim H
Mol Imaging Biol; 2012 Apr; 14(2):237-44. PubMed ID: 21494920
[TBL] [Abstract][Full Text] [Related]
16. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
Skrypek N; Duchêne B; Hebbar M; Leteurtre E; van Seuningen I; Jonckheere N
Oncogene; 2013 Mar; 32(13):1714-23. PubMed ID: 22580602
[TBL] [Abstract][Full Text] [Related]
17. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity.
García-Manteiga J; Molina-Arcas M; Casado FJ; Mazo A; Pastor-Anglada M
Clin Cancer Res; 2003 Oct; 9(13):5000-8. PubMed ID: 14581375
[TBL] [Abstract][Full Text] [Related]
18. Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft.
Kotopoulis S; Delalande A; Popa M; Mamaeva V; Dimcevski G; Gilja OH; Postema M; Gjertsen BT; McCormack E
Mol Imaging Biol; 2014 Feb; 16(1):53-62. PubMed ID: 23877869
[TBL] [Abstract][Full Text] [Related]
19. Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.
Tsujie M; Nakamori S; Nakahira S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Anticancer Res; 2007; 27(4B):2241-9. PubMed ID: 17695509
[TBL] [Abstract][Full Text] [Related]
20.
Tadros S; Shukla SK; King RJ; Gunda V; Vernucci E; Abrego J; Chaika NV; Yu F; Lazenby AJ; Berim L; Grem J; Sasson AR; Singh PK
Cancer Res; 2017 Oct; 77(20):5503-5517. PubMed ID: 28811332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
